Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Krystal Biotech Inc

NIVF

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

PTIXW

PBMWW

NIVFW

PTIX

SLGL

Kirby (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEX#NYSE">KEX</a>) has outperformed the market over the past 5 years by 2.3% on an annualized basis producing an average annual return of 16.94%. Currently, Kirby has a market capitalization of $5.94 billion. 
Buying $1000 In KEX: If an investor had bought $1000 of KEX stock 5 years ago, it would be worth $2,095.47 today based on a price of $104.48 for KEX at the time of writing.
<h3>Kirby's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746229512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Agnico Eagle Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) has outperformed the market over the past 10 years by 2.98% on an annualized basis producing an average annual return of 13.47%. Currently, Agnico Eagle Mines has a market capitalization of $55.88 billion. 
Buying $100 In AEM: If an investor had bought $100 of AEM stock 10 years ago, it would be worth $362.54 today based on a price of $111.15 for AEM at the time of writing.
<h3>Agnico Eagle Mines's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746227716_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

UBS analyst Andrew Spinola maintains Viavi Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) with a Neutral and lowers the price target from $11.5 to $11.

Price Target

Analyst Ratings

VIAV

UBS Maintains Neutral on Viavi Solutions, Lowers Price Target to $11

UBS analyst Taylor McGinnis maintains Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) with a Buy and lowers the price target from $175 to $150.

TWLO

UBS Maintains Buy on Twilio, Lowers Price Target to $150

UBS analyst Karl Keirstead maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Neutral and lowers the price target from $230 to $215.

TEAM

UBS Maintains Neutral on Atlassian, Lowers Price Target to $215

UBS analyst A.J. Rice maintains Service Corp Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCI#NYSE">SCI</a>) with a Buy and lowers the price target from $90 to $88.

UBS Maintains Buy on Service Corp Intl, Lowers Price Target to $88

UBS analyst Seth Gilbert maintains Open Text (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTEX#NASDAQ">OTEX</a>) with a Neutral and lowers the price target from $32 to $28.

OTEX

UBS Maintains Neutral on Open Text, Lowers Price Target to $28

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 20 years by 6.5% on an annualized basis producing an average annual return of 14.72%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $111.99 billion. 
Buying $1000 In MMC: If an investor had bought $1000 of MMC stock 20 years ago, it would be worth $15,188.11 today based on a price of $227.29 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746226815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Marsh & McLennan Cos 20 Years Ago Would Be Worth This Much Today

UBS analyst Peter Grom maintains Utz Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTZ#NYSE">UTZ</a>) with a Neutral and lowers the price target from $15 to $13.5.

UBS Maintains Neutral on Utz Brands, Lowers Price Target to $13.5

UBS analyst Peter Grom maintains Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) with a Neutral and lowers the price target from $175 to $170.

UBS Maintains Neutral on Hershey, Lowers Price Target to $170

UBS analyst Joseph Spak maintains General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) with a Neutral and lowers the price target from $51 to $50.

UBS Maintains Neutral on General Motors, Lowers Price Target to $50

UBS analyst Taylor McGinnis maintains Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) with a Buy and lowers the price target from $22 to $19.

Comments

Krystal Biotech

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL